MSP Compliance Blog

Expert summary, analysis and recommendations on issues impacting Medicare Secondary Payer compliance.

Specialty Pharmacy Invades Workers’ Compensation

Posted on February 22, 2014 by Rita Wilson

According to a recent issue of Workcompwire, “specialty medications”, drugs that may require special handling, distribution, administration and patient management, are beginning to have a significant impact on workers compensation.  With specialty conditions such as hepatitis C, rheumatoid arthritis, and multiple sclerosis occurring through direct or indirect…

Read more

The WSJ Picks Up NAMSAP Press Release

Posted on April 22, 2013 by Tower MSA

Recently, one of the many but ongoing successes for Tower MSA has occurred. The Wall Street Journal and others covered CEO Rita Ayers’ discussion on pharmacy trends during NAMSAP’s Annual Meeting and Educational Conference on April 25. The Wall Street…

Read more

The FDA Focuses New Attention on Compounding Pharmacies

Posted on April 17, 2013 by Rita Wilson

According to an article released by NBC News on April 11, 2013, the FDA posted reports on its web site for 28 of 31 compounding pharmacies it inspected between February and April listing a raft of violations ranging from inappropriate…

Read more

What Can Workers’ Comp Learn About Compounds From the Meningitis Outbreak?

Posted on October 29, 2012 by Rita Wilson

As of Tuesday, the Centers for Disease Control and Prevention reported 317 meningitis cases across several states, including 24 deaths. According to a preliminary report released on Monday, investigators from the Massachusetts Department of Public Health found “serious health and safety deficiencies” at…

Read more

When NOT to Authorize an Additional MRI

Posted on October 24, 2012 by Tower MSA

Additional MRI States that follow the Official Disability Guidelines (ODG) do not need to authorize an additional MRI unless there are specific changes in pathology. The ODG states that ³MRI¹s are test of choice for patients with prior back surgery, but…

Read more